Results 41 to 50 of about 369,109 (345)

What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?

Haseki Tıp Bülteni, 2017
Aim: There is still uncertainty today regarding the prostate specific antigen (PSA) threshold for prostate biopsy. From this point of view, we aimed to investigate the PSA threshold for prostate biopsy in this study.
Hasan Deliktaş, Hayrettin Şahin
doaj   +1 more source

Western Blotting Analysis of Antibodies to Prostate-Specific Antigen: Specificities for Prostate-Specific Antigen and Prostate-Specific Antigen Fragments

Tumor Biology, 1999
Approximately 40% of the prostate-specific antigen (PSA) purified from seminal fluid comprises cleaved or fragmented forms of PSA. These fragments are observed by reduced SDS-PAGE and have been identified in preparations of purified seminal plasma. The comparative analysis of 53 antibodies, submitted to an international PSA Workshop, with different PSA
T J, Wang, H J, Linton, R L, Sokoloff, L S, Grauer, H G, Rittenhouse, R L, Wolfert   +5 more
openaire   +2 more sources

Investigation of prostate specific antigen glycosylation [PDF]

Journal of the Serbian Chemical Society, 2000
In the present work, prostate specific antigen (PSA) glycosylation was examined by lectin affinity methods. The results obtained indicated that PSA purified from human seminal plasma contained at least one bianntenary N-linked oligosaccharide ...
Marinović Vesna, Čuperlović Margita
doaj   +3 more sources

Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer

Baghdad Journal of Biochemistry and Applied Biological Sciences, 2020
Background: Prostate cancer is one of the most common cancers in men, worldwide. Many markers are suggested for prostate cancer with different specificity and sensitivity.
Amal A. Hussein, Rayah Baban, Alaa Hussein   +2 more
doaj  

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources

PROSTATE-SPECIFIC ANTIGEN VELOCITY AND REPEATED MEASURES OF PROSTATE-SPECIFIC ANTIGEN

Urologic Clinics of North America, 1997
Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer.
H B, Carter, J D, Pearson
openaire   +2 more sources

Clinical Implications of Nadir Serum Prostate-Specific Antigen Levels After Transurethral Enucleation of the Prostate

Frontiers in Oncology, 2022
ObjectiveProstate-specific antigen levels after transurethral enucleation of the prostate may serve as indicators of residual cancer foci. The objective of this study was to investigate the association between the post-transurethral enucleation of the ...
Yung-Ting Cheng, Yung-Ting Cheng, Jian-Hua Hong, Yu-Chuan Lu, Yi-Kai Chang, Shih-Chun Hung, Kuo-Kang Feng, Shih-Ping Liu, Po-Ming Chow, Hong-Chiang Chang, Chung-Hsin Chen, Yeong-Shiau Pu   +11 more
doaj   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer

Cancer Management and Research, 2020
Xiaojing Bai,1,2,* Yumei Jiang,1,2,* Xinwei Zhang,1,2 Meiyu Wang,3 Juanhua Tian,1 Lijun Mu,1 Yuefeng Du1,2 1Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, People’s Republic of ...
Bai X, Jiang Y, Zhang X, Wang M, Tian J, Mu L, Du Y   +6 more
doaj  

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

BMC Cancer, 2019
Background Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer potentially have financial and ...
Joshua P. Schiff, Patrick Cotogno, Allison Feibus, Peter Steinwald, Elisa Ledet, Brian Lewis, Oliver Sartor   +6 more
doaj   +1 more source